BioNTech (BNTX) vs Summit Therapeutics (SMMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
BioNTech (BNTX) has outperformed Summit Therapeutics (SMMT) over the past year, losing 7.2% versus a loss of 22.3%. Over five years, SMMT leads with a +241.6% price change compared with -60.9% for BNTX. BioNTech is the larger company by market cap ($24.36 billion vs $14.03 billion), about 1.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTX | SMMT |
|---|---|---|
| Share price | $96.96 | $17.59 |
| Market cap | $24.36B | $14.03B |
| 1-day change | +5.32% | +2.45% |
| YTD return | +1.85% | +0.57% |
| 1-year return | -7.20% | -22.34% |
| 5-year return | -60.85% | +241.55% |
| EPS (TTM) | $-7.83 | $-1.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-1.08B |
| 52-week high | $124.00 | $29.23 |
| 52-week low | $79.52 | $12.07 |
| Distance from 52-week high | -21.81% | -39.82% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +19.85% | +69.30% |
| Average volume | 1.17M | 5.87M |
| Shares outstanding | 251.20M | 797.75M |
| Employees | 7,807 | 265 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BNTX has outperformed SMMT by 15.1 percentage points over the past year.
About BioNTech
BNTX stock →BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees
About Summit Therapeutics
SMMT stock →Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).
Health Care · Biotechnology: Pharmaceutical Preparations · 265 employees
BNTX vs SMMT FAQ
Which is bigger, BioNTech or Summit Therapeutics?
BioNTech (BNTX) is larger, with a market capitalization of $24.36B compared with $14.03B for Summit Therapeutics (SMMT).
Which stock has performed better over the past year, BNTX or SMMT?
BNTX returned -7.20% over the past 12 months, compared with -22.34% for SMMT (price return, excluding dividends). Past performance does not predict future results.
Are BioNTech and Summit Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for BioNTech and Biotechnology: Pharmaceutical Preparations for Summit Therapeutics.